| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
IN8bio Inc. Common Stock (NASDAQ: INAB)
INAB Technical Analysis
5
| As on 11th Mar 2025 INAB STOCK Price closed @ 0.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.07 & Strong Sell for SHORT-TERM with Stoploss of 0.97 we also expect STOCK to react on Following IMPORTANT LEVELS. |
INABSTOCK Price
| Open | 0.24 | Change | Price | % |
| High | 0.25 | 1 Day | -0.01 | -4.00 |
| Low | 0.23 | 1 Week | -0.03 | -11.11 |
| Close | 0.24 | 1 Month | -0.03 | -11.11 |
| Volume | 1727897 | 1 Year | -0.92 | -79.31 |
| 52 Week High 2.34 | 52 Week Low 0.23 | ||||
NASDAQ USA Most Active Stocks
| SYRS | 0.14 | 55.56% |
| AMRS | 0.14 | 100.00% |
| BHAT | 0.04 | 33.33% |
| NVDA | 108.76 | 1.66% |
| CUTR | 0.11 | -15.38% |
| AWH | 0.18 | -10.00% |
| TSLA | 230.58 | 3.79% |
| LMDX | 0.02 | 0.00% |
| LCID | 2.09 | 0.48% |
| AAL | 11.46 | -8.32% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| INAB Daily Charts |
INAB Intraday Charts |
Whats New @ Bazaartrend |
INAB Free Analysis |
|
|
INAB Important Levels Intraday
| RESISTANCE | 0.28 |
| RESISTANCE | 0.27 |
| RESISTANCE | 0.26 |
| RESISTANCE | 0.25 |
| SUPPORT | 0.23 |
| SUPPORT | 0.22 |
| SUPPORT | 0.21 |
| SUPPORT | 0.20 |
INAB Forecast March 2025
| 4th UP Forecast | 0.68 |
| 3rd UP Forecast | 0.54 |
| 2nd UP Forecast | 0.45 |
| 1st UP Forecast | 0.37 |
| 1st DOWN Forecast | 0.11 |
| 2nd DOWN Forecast | 0.03 |
| 3rd DOWN Forecast | -0.06 |
| 4th DOWN Forecast | -0.2 |
INAB Weekly Forecast
| 4th UP Forecast | 0.80 |
| 3rd UP Forecast | 0.62 |
| 2nd UP Forecast | 0.51 |
| 1st UP Forecast | 0.40 |
| 1st DOWN Forecast | 0.08 |
| 2nd DOWN Forecast | -0.03 |
| 3rd DOWN Forecast | -0.14 |
| 4th DOWN Forecast | -0.32 |
INAB Forecast2025
| 4th UP Forecast | 4.6 |
| 3rd UP Forecast | 3.2 |
| 2nd UP Forecast | 2.34 |
| 1st UP Forecast | 1.47 |
| 1st DOWN Forecast | -0.99 |
| 2nd DOWN Forecast | -1.86 |
| 3rd DOWN Forecast | -2.72 |
| 4th DOWN Forecast | -4.12 |
IN8bio Inc. Common Stock ( NASDAQ USA Symbol : INAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
INAB Business Profile
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. The company develops INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York. Address: 79 Madison Avenue, New York, NY, United States, 10016
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service